Ning Xie

Ning Xie

Auto-generated profile, based on publicly available information

Ning Xie

Biomedical Cybernetics Laboratory, Harvard Medical School, Boston, USA

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 October 2022 in Journal of Medical Internet Research
Verified
Journal Article
Open access
BRBedda Rosario
Bedda Rosario
AZAndrew Zhang
Andrew Zhang
MPMehool Patel
Mehool Patel
ARAmol Rajmane
Amol Rajmane
NXNing Xie
Ning Xie
GAGil Alterovitz
Gil Alterovitz
Background: COVID-19 has been observed to be associated with venous and arterial thrombosis. The inflammatory disease prolongs hospitalization, and preexisting comorbidities can intensity the thrombotic burden in patients with COVID-19. However, venous thromboembolism, arterial thrombosis, and other vascular complications may go unnoticed in critical care settings. Early risk stratification is paramount in the COVID-19 patient population for proactive monitoring of thrombotic complications. Objective: The aim of this exploratory research was to characterize thrombotic complication risk factors associated with COVID-19 using information from electronic health record (EHR) and insurance claims databases. The goal is to develop an approach for analysis using real-world data evidence that can be generalized to characterize thrombotic complications and additional conditions in other clinical settings as well, such as pneumonia or acute respiratory distress syndrome in COVID-19 patients or in the intensive care unit. Methods: We extracted deidentified patient data from the insurance claims database IBM MarketScan, and formulated hypotheses on thrombotic complications in patients with COVID-19 with respect to patient demographic and clinical factors using logistic regression. The hypotheses were then verified with analysis of deidentified patient data from the Research Patient Data Registry (RPDR) Mass General Brigham (MGB) patient EHR database. Data were analyzed according to odds ratios, 95% CIs, and P values. Results: The analysis identified significant predictors (P<.001) for thrombotic complications in 184,831 COVID-19 patients out of the millions of records from IBM MarketScan and the MGB RPDR. With respect to age groups, patients 60 years and older had higher odds (4.866 in MarketScan and 6.357 in RPDR) to have thrombotic complications than those under 60 years old. In terms of gender, men were more likely (odds ratio of 1.245 in MarketScan and 1.693 in RPDR) to have thrombotic complications than women. Among the preexisting comorbidities, patients with heart disease, cerebrovascular diseases, hypertension, and personal history of thrombosis all had significantly higher odds of developing a thrombotic complication. Cancer and obesity were also associated with odds>1. The results from RPDR validated the IBM MarketScan findings, as they were largely consistent and afford mutual enrichment. Conclusions: The analysis approach adopted in this study can work across heterogeneous databases from diverse organizations and thus facilitates collaboration. Searching through millions of patient records, the analysis helped to identify factors influencing a phenotype. Use of thrombotic complications in COVID-19 patients represents only a case study; however, the same design can be used across other disease areas by extracting corresponding disease-specific patient data from available databases.

13 August 2026 in npj Aging
Verified
Journal Article
Open access
PDF file
RMRajarshi Mandal
Rajarshi Mandal
NXNing Xie
Ning Xie
GAGil Alterovitz
Gil Alterovitz
We developed an interpretable blood-based epigenetic clock to estimate DNA methylation age and identify disease-specific DNA methylation alterations. Using 8233 Illumina methylomes from healthy controls and nine age-associated diseases, we used ridge selection to retain 4855 CpG sites and benchmarked 20 regression architectures with Bayesian hyperparameter optimization. Tree-based boosting models performed best, and a weighted ensemble achieved a mean absolute error of 2.54 years on held-out test data, outperforming established clocks evaluated under the same conditions. External validation in the independent EPIC cohort GSE132203 provided initial cross-platform support for transferability (MAE 3.04 years) and a modest but significant association with GEO-reported age acceleration (r = 0.145, p = 0.041). PaCMAP embeddings revealed structured aging trajectories and disease-enriched neighborhoods. Model interpretation highlighted loci including ELOVL2, FHL2, KLF14, CD8A, LAG3, SMAD2, and NSD1, while Enrichr identified enrichment of REST, microRNA, and histone modification programs. The clock identified departures from the healthy control methylation age model across diseases, with the greatest absolute deviation observed in stroke patients.